Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non- steroidal estrone sulfatase inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 68, Issue 1-2, 1999, Pages 31-40

  Kolli, Aparna ^a   Chu, Guo Hua ^b   Rhodes, Michael E ^a   Inoue, Kengo ^c   Selcer, Kyle W ^a   Li, Pui Kai ^b  

^a BAYER CORPORATION   (United States)

^b DUQUESNE UNIVERSITY   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; ESTRONE; ESTRONE 3 O SULFAMATE; ESTRONE SULFATASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; ENZYME ACTIVITY; ESTROGEN BLOOD LEVEL; HORMONAL CARCINOGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE;

AMINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; MICROSOMES; NEOPLASMS, HORMONE-DEPENDENT; PLACENTA; PREGNANCY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATASES; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0033062017     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00159-9     Document Type: Article

References (24)

1. Noel C.T., Reed M.J., Jacobs H.S., James V.H.T. The plasma concentration of oestrone sulphate in postmenopausal women: Lack of diurnal variation, effect of ovariectomy age and weight. J. Steroid Biochem. 14:1981;1101-1105.
2. Samojlik E., Santen R.J., Worgul T.J. Plasma estrone sulfate: assessment of reduced estrogen production during treatment of metastatic breast cancer. Steroids. 39:1982;497-503.
3. Pasqualini J.R., Chetrite G., Nguyen B.-L., Maloche C., Delalonde L., Talbi M., Feinstein M.-C., Blacker C., Botella J., Paris J. Estrone sulfate-sulfatase and 17b-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J. Steroid Biochem. Mol. Biol. 53:1995;407-412.
4. Santner S.J., Feil P.D., Santen R.J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance vs. the aromatase pathway. J. Clin. Endocrinol. Metab. 59:1984;29-33.
5. Howarth N.M., Purohit A., Reed M.J., Potter B.V.L. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 37:1994;219-221.
6. Purohit A., Williams G.J., Howarth N.M., Potter B.V.L., Reed M.J. Inactivation of steroid sulfatase by an active-site directed inhibitor estrone-3-O-sulphamate. Biochemistry. 34:1995;11508-11514.
7. Purohit A., Williams G.J., Roberts C.J., Potter B.V.L., Reed M.J. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by estrone-3-sulphamate. Int. J. Cancer. 63:1995;106-111.
8. Elger W., Schwarz S., Hedden A., Reddersen G., Schneider B. Sulfamates of various estrogens-prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 55:1995;396-403.
9. Li P.K., Milano S., Kluth L., Rhodes M.E. Synthesis and sulfatase inhibitory activities of nonsteroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 59:1996;41-48.
10. Chu G.H., Milano S., Kluth L., Rhodes M.E., Johnson D.A., Li P.K. Structure-activity relationship studies of the amide functionality in (p-O-sulfamoyl)-N-alkanoyl tyramines as estrone sulfatase inhibitor. Steroids. 62:1997;530-535.
11. Ryan K.J. Biological aromatization of steroids. J. Biol. Chem. 234:1959;268-272.
12. James V.H.T., Reed M.J. Steroid hormones and human cancer. Cancer Res. Ther. 14:1980;471-487.
13. Millington D.S. Determination of hormonal steroid concentrations in biological extracts by high resolution fragmentography. J. Steroid Biochem. 6:1975;239-245.
14. Edery M., Goussard J., Dehennin L., Scholler R., Reiffsteck J., Drosdowsky M.A. Endogenous oestradiol-17b concentration in breast tumors determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur. J. Cancer. 17:1981;115-120.
15. Reed M.J., Purohit A., Howarth N.M., Potter B.V.L. Steroid sulphatase inhibitors: a new endocrine therapy. Drug Future. 19:1994;673-680.
16. Duncan L., Puroit A., Howarth N.M., Potter B.V.L., Reed M.J. Inhibition of estrone sulfate activity by estrone-3-methylthhiophosphonate. Cancer Res. 53:1993;298-303.
17. Howarth N.M., Cooper G., Purohit A., Duncan L., Reed M.J., Potter B.V.L. Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone-3-methylthiophosphonate a potent inhibitor of estrone sulfatase. Bioorg. Med. Chem. Lett. 3:1993;313-318.
18. Selcer K., Li P.K. Estrogenicity antiestrogenicity and estrone sulfatase inhibition of estrone-3-amine and estrone-3-thiol. J. Steroid Biochem. Mol. Biol. 52:1995;281-286.
19. Selcer K.W., Jagannathan S., Rhodes M.E., Li P.K. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone 3-amino derivatives. J. Steroid Biochem. & Mol. Biol. 59:1996;83-91.
20. Woo L.W.L., Purohit A., Reed M.J., Potter B.V.L. Active site-directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. J. Med. Chem. 39:1996;1349-1351.
21. Purohit A., Woo L.W.L., Singh A., Winterborn C.J., Potter B.V.L., Reed M.J. In vitro activity of 4-methylcoumarin-7-O-sulfamate a nonsteroidal nonestrogenic steroid sulfatase inhibitor. Cancer Res. 56:1996;4950-4955.
22. Selcer K.W., Hedge P., Li P.K. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines. Cancer Res. 57:1997;702-707.
23. Purohit A., Reed M.J. Oestrogen sulphatase activity in hormone-dependent and hormone- independent breast cancer cells: modulation by steroidal and nonsteroidal therapeutic agents. Int. J. Cancer. 50:1992;901-905.
24. Li P.K., Chu G.H., Peters A., Selcer K.W. Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids. 63:1998;425-432.